Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Company reaffirms commitment to reduce the global burden of HPV-related diseases, including certain cancers
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
MASH is a chronic and progressive liver disease characterised by fat accumulation and inflammation in the liver,
The US FDA's clearance of the trial marks the first global registrational Phase III trial for olverembatinib in patients with CP-CML to be conducted.
Exblifeb demonstrates remarkable efficacy in treating complicated Urinary Tract Infections (cUTI), pneumonia
Submission to be reviewed under FDA real-time oncology review and Project Orbis
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Subscribe To Our Newsletter & Stay Updated
